Number of pages: 41
Posted: 31 May 2019
Aung Naing,
Funda Meric-Bernstam,
Bettzy Stephen,
Daniel D. Karp,
Joud Hajjar,
Jordi Rodon Ahnert,
Sarina A. Piha-Paul,
Rivka Colen,
Camilo Jimenez,
Kanwal Raghav,
Renata Ferrarotto,
Shi-Ming Tu,
Matthew Campbell,
Linghua Wang,
Sharjeel H. Sabir,
Coya Tapia,
Chantale Bernatchez,
Michael Frumovitz,
Nizar M. Tannir,
Vinod Ravi,
Saria Khan,
Jeane M. Painter,
Jing Gong,
Anas Ashalwa,
Lacey M. McQuinn,
Mingxuan Xu,
Sara Ahmed,
Vivek Subbiah,
David S. Hong, Shubham Pant,
TImothy A. Yap,
Apostolia M. Tsimberidou,
Ecaterina E. Ileana Dumbrava,
Filip Janku,
Siqing Fu,
Richard M. Simon,
Kenneth R. Hess,
Gauri R. Varadhachary and
Mouhammed A. Habra
University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, Baylor College of Medicine, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston, Health Science Center at Houston (UTHealth), MD Anderson Cancer Center, Department of Radiology, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Thoracic/Head and Neck Medical Oncology, University of Texas at Houston - Department of Genitourinary Medical Oncology, University of Texas at Houston - Department of Genitourinary Medical Oncology, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Genitourinary Medical Oncology, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas Rio Grande Valley (UTRGV) (Formerly University of Texas-Pan American), University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, R Simon Consulting, University of Texas at Houston - Department of Biostatistics, University of Texas at Houston - MD Anderson Cancer Center and University of Texas at Houston - MD Anderson Cancer Center
